Double-stranded oligonucleotide for inhibiting USP20 gene expression and application thereof
By developing double-stranded oligonucleotide conjugates that inhibit USP20 gene expression, the problem that the prior art cannot effectively inhibit USP20 gene expression is solved, effectively treating and preventing USP20-related diseases, and significantly improving the therapeutic effect.
Patent Information
- Application Number
- CN202310586700.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
The existing RNAi drugs targeting USP20 have not yet been launched, and cannot effectively inhibit USP20 gene expression, resulting in the inability to effectively prevent and treat metabolic diseases related to USP20 such as hyperlipidemia, hepatic fat, obesity and diabetes.
Develop a double-stranded oligonucleotide that inhibits the expression of the USP20 gene, forming a double-stranded oligonucle by forming complementary or substantially complementary sense and antisense strands, combined with pharmaceutically acceptable targeting groups and delivery auxiliary groups. Glycolate conjugates, used to reduce USP20 gene expression, thereby treating related diseases.
In vitro cell experiments, excellent USP20 gene expression regulatory activity was shown, and the inhibition rate of the target gene USP20 can reach more than 93%. It effectively treats and prevents disease symptoms related to USP20 gene expression and has good application prospects.
Smart Images

Figure CN119020355A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nucleic acid drugs, and in particular to a double-stranded oligonucleotide for inhibiting USP20 gene expression and an application thereof. Background Art
[0002] Ubiquitin-specific protease (USP20) regulates cholesterol metabolism by a unique mechanism. Studies have found that knocking down USP20 can effectively weaken the stability of HMG-CoA reductase (HMGCR, the rate-limiting enzyme in the cholesterol biosynthesis pathway), promote its degradation to weaken the catalytic cholesterol synthesis, and thus inhibit the synthesis and production of cholesterol at the source. Specifically, HMGCR, the rate-limiting enzyme in the cholesterol synthesis pathway, is significantly upregulated after eating, among which phosphorylation modification of ubiquitin-specific protease 20 (USP20, a deubiquitinating enzyme) plays an important role. Postprandial elevated glucose and insulin stimulate mTORC1 to phosphorylate USP20 at S132 and S134. USP20 binds to gp78, is recruited to the HMGCR complex and antagonizes its degradation, thereby stabilizing HMGCR and promoting cholesterol synthesis. Genetic deletion or pharmacological inhibition of USP20 can also significantly reduce diet-induced weight gain, reduce lipid levels in serum and liver, improve insulin sensitivity and increase energy expenditure. In addition, under the condition of high-sugar and high-fat diet, inhibiting USP20 activity can significantly reduce cholesterol and triglyceride levels, reduce body weight, and improve insulin sensitivity. Cholesterol is an important metabolite in the body and is associated with many physiological and pathological processes. Cholesterol-lowering drugs play an important role in the prevention of atherosclerotic cardiovascular disease (ASCVD). The above studies show that USP20 can be used as a new liver-targeted drug target, and is expected to treat metabolic diseases including hyperlipidemia, liver fat, obesity and diabetes.
[0003] Small interfering RNA (siRNA) can inhibit or block the expression of target genes in a sequence-specific manner based on the RNA interference mechanism, thereby achieving the purpose of treating diseases. Therefore, by inhibiting the expression of the USP20 gene, diseases caused by abnormal cholesterol levels, especially hyperlipidemia, liver fat, obesity and diabetes, can be prevented and treated at the cellular level. In addition, due to the unique mechanism of action of USP20, inhibiting the expression of the target gene can not only control the biosynthesis of cholesterol in daily life to prevent and / or control metabolic syndrome, but also increase heat production, promote weight loss, and increase sensitivity to insulin. There are currently no RNAi drug products targeting USP20 on the market. Therefore, there is a need for siRNA drugs that can inhibit USP20 gene expression and can treat diseases related to USP20 gene expression such as hyperlipidemia.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] In response to the clinical needs of lowering blood lipids, controlling metabolic syndrome and cardiovascular and cerebrovascular diseases, the present invention uses the deubiquitinating enzyme USP20 as a target to develop a small nucleic acid molecule drug that can lower cholesterol levels and prevent or control metabolic syndrome. The first purpose of the present invention is to provide a double-stranded oligonucleotide and its conjugate, pharmaceutical composition, kit for inhibiting USP20 gene expression, and methods and uses thereof for inhibiting or reducing USP20 gene expression or treating diseases or symptoms mediated by USP20 gene.
[0006] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:
[0007] According to one aspect of the present invention, a double-stranded oligonucleotide for inhibiting the expression of USP20 gene is provided, wherein the double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are complementary or substantially complementary to form a double-stranded region; the substantially complementary means that the sense strand and the antisense strand have a mismatch of no more than 3 nucleotides in the double-stranded region;
[0008] wherein the sense strand comprises at least 15 consecutive nucleotides substantially identical to SEQ ID NO: 349, wherein the substantially identical means that the sense strand has no more than 3 nucleotide differences from at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 349;
[0009] wherein the antisense strand comprises at least 15 nucleotides and is complementary or substantially complementary to the sense strand;
[0010] Each nucleotide of the double-stranded oligonucleotide is an unmodified or modified nucleotide;
[0011] Optionally, at least one nucleotide in the double-stranded oligonucleotide is modified.
[0012] According to another aspect of the present invention, a double-stranded oligonucleotide conjugate is provided, wherein the double-stranded oligonucleotide conjugate comprises the above-mentioned double-stranded oligonucleotide and a conjugation group; wherein the conjugation group includes a pharmaceutically acceptable targeting group and / or a delivery auxiliary group.
[0013] According to one aspect of the present invention, there is provided a use of the above double-stranded oligonucleotide or the above double-stranded oligonucleotide conjugate in the preparation of a drug for alleviating, preventing and / or treating a disease or condition mediated by the USP20 gene.
[0014] According to one aspect of the present invention, there is provided a pharmaceutical composition comprising the above-mentioned double-stranded oligonucleotide, its isomers or pharmaceutically acceptable salts thereof, or the above-mentioned double-stranded oligonucleotide conjugate, its isomers or pharmaceutically acceptable salts thereof; and further comprising a therapeutic agent and / or pharmaceutically optional excipients.
[0015] According to one aspect of the present invention, a kit is provided, comprising the above-mentioned double-stranded oligonucleotide, the above-mentioned double-stranded oligonucleotide conjugate, or the above-mentioned pharmaceutical composition.
[0016] According to one aspect of the present invention, a method for inhibiting USP20 gene expression is provided, the method comprising administering the above double-stranded oligonucleotide or the above double-stranded oligonucleotide conjugate, or the above pharmaceutical composition to a subject.
[0017] According to one aspect of the present invention, a method for alleviating, treating and / or preventing a disease or condition mediated by USP20 is provided, the method comprising administering the above double-stranded oligonucleotide or the above double-stranded oligonucleotide conjugate to a subject, or administering the above pharmaceutical composition to a subject.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The double-stranded oligonucleotide and pharmaceutical composition provided by the present invention show excellent USP20 gene expression regulation activity in in vitro cell experiments. For example, the double-stranded oligonucleotide of the present invention shows excellent USP20 mRNA inhibition activity in C57BL / 6 mouse cells, and at a siRNA concentration of 10 nM, the target gene USP20 inhibition rate can reach up to more than 93% (RZ004027).
[0020] This shows that the double-stranded oligonucleotides, pharmaceutical compositions and oligonucleotide conjugates provided by the present disclosure can effectively regulate the expression level of the target gene USP20, and thus can effectively treat and / or prevent disease symptoms related to the mRNA level expressed by the USP20 gene, and have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0022] Figure 1 is the relative expression level of the target gene in mice after administration of siRNA conjugates from RZ004001 to RZ004027;
[0023] Figure 2 The inhibitory activity of the target gene in Hela cells after administration of siRNA conjugates of RZ004027-RZ004054;
[0024] Figure 3 is the relative expression level of the target gene in mice after administration of RZM04001;
[0025] Figure 4 Figure 2 shows the cholesterol levels in the serum of mice at different time points after administration of RZM04001. DETAILED DESCRIPTION
[0026] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0027] [definition]
[0028] In this article, above and below, unless otherwise specified, capital letters A (adenine), U (uracil), G (guanine), C (cytosine), and T (thymine, which also represents uracil in the sequence table) represent the base composition of nucleotides; lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a 2′-methoxy-modified nucleotide; lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a 2′-fluoro-modified nucleotide; (moe) indicates that the nucleotide adjacent to the left of the combination mark is a 2′-methoxyethyl-modified nucleotide; lowercase letter s indicates that the two nucleotides adjacent to the left and right of the letter s are connected by a thiophosphate group, and L96 represents the structural part connected to Nu (double-stranded oligonucleotide) as shown in the following formula (II).
[0029]
[0030] Herein, "fluorinated modified nucleotides" or "2'-fluorinated modified nucleotides" refer to nucleotides in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by fluorine, and "non-fluorinated modified nucleotides" refer to nucleotides or nucleotide analogs in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by a non-fluorinated group. The "methoxy-modified nucleotides" or "2'-methoxyethyl-modified nucleotides" refer to nucleotides in which the 2' hydroxyl group of the ribose group is replaced by a methoxy group or a methoxyethyl group. "Methoxy-modified nucleotides" are also recorded as 2'-OMe or 2'-O-methyl modified nucleotides, which can be used interchangeably. "2'-methoxyethyl-modified nucleotides" are also recorded as 2'-MOE modified; 2'-deoxynucleotides refer to nucleotides in which the 2' position of the ribose group is hydrogen.
[0031] Herein, a double-stranded oligonucleotide is composed of two chains, wherein the chain that binds to the target sequence is called the antisense chain or guide chain, and the other chain is called the sense chain or passenger chain. The term "antisense chain" refers to such a chain of a double-stranded oligonucleotide, wherein the chain includes a region that is completely or substantially complementary to the target sequence. The term "sense chain" refers to such a chain of a double-stranded oligonucleotide, wherein the chain includes a region that is substantially complementary to the region of the antisense chain as the term defined herein. The term "complementary region" refers to a region on the antisense chain that is completely or substantially complementary to the target sequence. In the case where the complementary region is not completely complementary to the target sequence, the mismatch can be located in the interior or terminal region of the molecule. As used herein, the term "complementary" refers to the ability of a first polynucleotide to hybridize with a second polynucleotide under certain conditions, such as stringent conditions. Herein, double-stranded oligonucleotides and siRNA can be used interchangeably.
[0032] As used herein, the expressions "complementary" and "reverse complementary" are used interchangeably and have the meanings known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one strand are each paired with the bases on the other strand in a complementary manner.
[0033] Herein, unless otherwise specified, "substantially reverse complementary" or "substantially complementary" means that there are no more than 3 base mismatches between the two nucleotide sequences involved; "substantially reverse complementary" means that there are no more than 1 base mismatch between the two nucleotide sequences; and "completely reverse complementary" means that there are no base mismatches between the two nucleotide sequences.
[0034] According to one aspect of the present invention, a double-stranded oligonucleotide for inhibiting USP20 gene expression is provided, wherein the double-stranded oligonucleotide can inhibit USP90 gene expression in mammals including humans, monkeys, rats or mice. The double-stranded oligonucleotide can inhibit USP20 gene expression in cells in vitro and can also inhibit USP90 gene expression in vivo.
[0035] The double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are complementary or substantially complementary to form a double-stranded region; the substantially complementary means that the sense strand and the antisense strand have a mismatch of no more than 3 nucleotides in the double-stranded region.
[0036] Wherein, the positive strand contains at least 15 consecutive nucleotides that are substantially identical to SEQ ID NO: 349, and the substantially identical means that there are 0, 1, 2 or 3 nucleotide differences between the positive strand and at least 15 consecutive nucleotides in the SEQ ID NO: 349 sequence.
[0037] The antisense strand comprises at least 15 nucleotides and is complementary or substantially complementary to the sense strand.
[0038] Each nucleotide of the double-stranded oligonucleotide may be an unmodified or modified nucleotide.
[0039] The target sequence of the double-stranded oligonucleotide for inhibiting USP20 gene expression provided by the present invention is derived from the sequence of mRNA formed during USP20 gene expression, and the nucleotide sequence is shown in SEQ ID NO: 349, which is the mRNA sequence shown in Genbank Accession No. NM_001110303.4.
[0040] In an alternative embodiment, at least one nucleotide in the double-stranded oligonucleotide is modified.
[0041] In an optional embodiment, the antisense strand is complementary or substantially complementary to at least 15, 16, 17, 18, 19, 20, 21, 22 or 23 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:349, wherein substantially complementary means there are 0, 1, 2 or 3 mismatches in the complementary region.
[0042] In an optional embodiment, the sense strand comprises at least 15 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 349 by 0, 1 or 2 nucleotides; and substantially all of the nucleotides of the sense strand and the antisense strand are modified nucleotides, and the length of the double-stranded region is 15-25bp, for example, but not limited to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25bp; wherein substantially all of the modified nucleotides means that the number of unmodified nucleotides on the strand does not exceed 5, for example, may be but not limited to 0, 1, 2, 3, 4 or 5, preferably does not exceed 3, and more preferably does not exceed 1.
[0043] In an alternative embodiment, the antisense strand comprises a sequence of at least 15 consecutive nucleotides that differs from any of the antisense sequences listed in Table 1 by 0, 1, 2 or 3 nucleotides, and wherein the sense strand comprises a sequence of at least 15 consecutive nucleotides that differs from any of the sense sequences listed in Table 1 by 0, 1, 2 or 3 nucleotides.
[0044] Table 1
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051] Table 2
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060] In an alternative embodiment, the sense strand comprises a sequence having no more than 0, 1 or 2 nucleotide differences from any sequence in SEQ ID NO: 1-7 and SEQ ID NO: 15-183; the antisense strand comprises a sequence having no more than 0, 1 or 2 nucleotide differences from any sequence in SEQ ID NO. 8-14 and SEQ ID NO. 184-348. In an alternative embodiment, the nucleotide sequence of the sense strand has 0 or 1 nucleotide difference from any nucleotide sequence selected from SEQ ID NO: 1-7 and SEQ ID NO: 15-183, and / or the nucleotide sequence of the antisense strand has 0 or 1 nucleotide difference from any nucleotide sequence selected from SEQ ID NO. 8-14 and SEQ ID NO. 184-348.
[0061] In an optional embodiment, the sense strand of the double-stranded oligonucleotide comprises the sequence of any sense strand shown in Table 1 or Table 2, and the antisense strand comprises the sequence of any antisense strand shown in Table 1 or Table 2;
[0062] Optionally, the double-stranded oligonucleotide is selected from the double-stranded oligonucleotides shown in any number in Table 1 or Table 2;
[0063] Preferably, the double-stranded oligonucleotide is selected from one or more of the modified or unmodified double-stranded oligonucleotides shown in the following numbers in Table 2: RN004006, RN004011, RN004015, RN004017, RN004018, RN004019, RN004020, RN004023, RN004024, RN004043, , RN004053, RN004054, RN004063, RN004066, RN004067, RN004074, RN004076, RN004077, RN004092, RN004093, RN004094, RN004096, RN004103, RN004110, RN004141, RN004164, RN004166;
[0064] Further preferably, the double-stranded oligonucleotide is selected from the modified or unmodified double-stranded oligonucleotides numbered RN004166, RN004020, RN004094, RN004141, RN004043, RN004164, and RN004092.
[0065] Further preferably, the double-stranded oligonucleotide is selected from the modified double-stranded oligonucleotides numbered RN004030, RN004033, RN004041, RN004043, RN004051, and RN004053.
[0066] In an alternative embodiment, the sense strand and / or antisense strand contains at least one ribose 2′ hydroxyl group replaced by a large group 2′-O(CH2) n OR substituted nucleotides, wherein n is 1 or 2, and R is selected from: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy; wherein the substituent is selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, amino, cycloalkyl with no more than 6 carbon atoms, aryl or heteroaryl with no more than 12 carbon atoms.
[0067] In an alternative embodiment, the nucleotides of the double-stranded oligonucleotide further include one or more of the following modifications:
[0068] 2′-O-methyl modified nucleotides, 2′-fluoro modified nucleotides, 2′-deoxy nucleotides, 2′-methoxyethyl modified nucleotides, 2′-alkyl modified nucleotides, 2′-amino-modified nucleotides, 2′-alkoxy modified nucleotides, locked nucleic acid modifications, non-locked nucleic acid modifications, 2′-O-allyl modifications, 2′-C-allyl modifications, abasic nucleotides, morpholino nucleotides, conformationally restricted nucleotides, constrained ethyl nucleotides, and phosphoramidate modifications.
[0069] In an alternative embodiment, the modification is selected from at least one of 2'-O-methyl modified nucleotides, 2'-fluoro-modified nucleotides, 2'-deoxy nucleotides, and phosphorothioate modified nucleotides.
[0070] In an alternative embodiment, at least one nucleotide on the sense strand and / or the antisense strand is modified.
[0071] In an alternative embodiment, all nucleotides in the sense strand and / or the antisense strand are modified nucleotides.
[0072] In an alternative embodiment, all nucleotides in the double-stranded oligonucleotide are modified.
[0073] In an alternative embodiment, the sense strand and / or the antisense strand contains at least one 2'-methoxyethyl modified nucleotide.
[0074] In an optional embodiment, the double-stranded oligonucleotide is modified as follows:
[0075] (1) Sense strand: 17-21 nt in length, preferably 19 nt; composed of alternating 2′-MOE modified, 2′-O-methyl modified regions and 2′-fluoro modified regions, each modified region having an independent length of 1 to 13 nucleotides, such as but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 nucleotides.
[0076] (2) Antisense strand: 19-23 nt in length, preferably 21 nt; composed of 2′-MOE modified, 2′-O-methyl modified, 2′-fluoro modified, and optionally unmodified or DNA modified regions, each modified region is independently 1 to 13 nucleotides in length, such as but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 nucleotides. The continuous nucleotide region from the 2nd to 5th position from the 5′ end and the continuous nucleotide region from the 1st to 3rd position from the 3′ end may be connected by a thiophosphate backbone.
[0077] In the above embodiment, the double-stranded oligonucleotide is further preferably modified as follows:
[0078] (1) Sense strand: from the 5′ end to the 3′ end, at least three of the 7th to 10th nucleotides in the nucleotide sequence of the sense strand are fluorinated modified nucleotides, and the remaining nucleotides in the sense strand of the double-stranded oligonucleotide are methoxy-modified or other modified nucleotides except fluorinated;
[0079] (2) Antisense strand: From the 5′ end to the 3′ end, at least four of the nucleotides at positions 2, 6, 9-10, 14 and 16 of the nucleotide sequence in the antisense strand are fluorinated modified nucleotides, and the nucleotides at the remaining positions of the antisense strand of the double-stranded oligonucleotide are methoxy-modified or other modified nucleotides except fluorinated modification.
[0080] In an optional embodiment, the double-stranded oligonucleotide is modified as follows:
[0081] (1) Sense strand: From the 5′ end to the 3′ end, the 5th, 7th, 8th and 9th nucleotides in the nucleotide sequence of the sense strand are fluorinated nucleotides, and the remaining nucleotides in the sense strand of the double-stranded oligonucleotide are methoxy-modified or nucleotides modified other than fluorinated;
[0082] (2) Antisense strand: From the 5′ end to the 3′ end, the nucleotides at positions 2, 6, 8, 14 and 16 of the nucleotide sequence in the antisense strand are fluorinated modified nucleotides, and the nucleotides at the remaining positions of the antisense strand of the double-stranded oligonucleotide are methoxy-modified or other modified nucleotides except fluorinated modification.
[0083] In an optional embodiment, the double-stranded oligonucleotide is modified as follows:
[0084] (1) Sense strand: From the 5′ end to the 3′ end, the 7th, 8th and 9th nucleotides in the nucleotide sequence of the sense strand are fluorinated modified nucleotides, and the remaining nucleotides in the sense strand of the double-stranded oligonucleotide are methoxy-modified nucleotides;
[0085] (2) Antisense strand: From the 5′ end to the 3′ end, the nucleotides at positions 2, 6, 14 and 16 in the nucleotide sequence of the antisense strand are fluorinated modified nucleotides, and the nucleotides at the remaining positions of the antisense strand of the double-stranded oligonucleotide are methoxy-modified nucleotides.
[0086] In an optional embodiment, the double-stranded oligonucleotide is modified as follows:
[0087] (1) Sense strand: From the 5′ end to the 3′ end, the nucleotides at positions 7 to 10 in the nucleotide sequence of the sense strand are fluorinated or MOE-modified nucleotides, and the nucleotides at the remaining positions of the sense strand of the double-stranded oligonucleotide are methoxy-modified or MOE-modified nucleotides;
[0088] (2) Antisense strand: From the 5′ end to the 3′ end, the nucleotides at positions 2, 6, 9, 14, and 16 of the nucleotide sequence in the antisense strand are fluorinated or MOE-modified nucleotides, and the nucleotides at the remaining positions of the antisense strand of the double-stranded oligonucleotide are methoxy-modified or MOE-modified nucleotides;
[0089] (3) The sense strand or the antisense strand contains at least one MOE-modified nucleotide.
[0090] In an optional embodiment, the double-stranded oligonucleotide is modified as follows:
[0091] (1) Sense strand: From the 5′ end to the 3′ end, the 7th, 8th and 9th nucleotides in the nucleotide sequence of the sense strand are fluorinated modified nucleotides, and the remaining nucleotides in the sense strand of the double-stranded oligonucleotide are methoxy-modified or MOE-modified nucleotides;
[0092] (2) Antisense strand: From the 5′ end to the 3′ end, the nucleotides at positions 2, 6, 10, 14 and 16 of the nucleotide sequence in the antisense strand are fluorinated modified nucleotides, and the nucleotides at the remaining positions of the antisense strand of the double-stranded oligonucleotide are methoxy- or MOE-modified nucleotides;
[0093] (3) The sense strand or the antisense strand contains at least one MOE-modified nucleotide.
[0094] In an optional embodiment, at least a portion of the phosphate groups in the phosphate sugar backbone of at least one single strand of the sense strand and the antisense strand of the double-stranded oligonucleotide is a phosphate group having a modified group;
[0095] In an optional embodiment, the phosphate group having a modified group is a phosphorothioate group formed by replacing at least one oxygen atom in the phosphodiester bond in the phosphate group with a sulfur atom;
[0096] Sense chain internucleoside linkage modification:
[0097] In an alternative embodiment, the sense strand of the double-stranded oligonucleotide contains at least 1-2 phosphorothioate internucleoside linkages;
[0098] In an alternative embodiment, any one of the phosphorothioate internucleoside linkages of the sense strand of the double-stranded oligonucleotide is located between the nucleotides at positions 1-3 from the 5′ end of the sense strand, and / or between the nucleotides at positions 1-3 from the 3′ end;
[0099] In alternative embodiments, the sense strand of the double-stranded oligonucleotide contains 1 or 2 phosphorothioate internucleoside linkages.
[0100] In alternative embodiments, any one of the phosphorothioate internucleoside linkages of the sense strand of the double-stranded oligonucleotide is located between nucleotides 1-3 from the 5' end and / or between nucleotides 1-3 from the 3' end of the sense strand.
[0101] In an alternative embodiment, the sense strand of the double-stranded oligonucleotide contains two phosphorothioate internucleoside linkages. In an alternative embodiment, the two phosphorothioate internucleoside linkages are optionally located between nucleotides at positions 1-3 from the 5' end of the sense strand; in an alternative embodiment, the two phosphorothioate internucleoside linkages are located between nucleotides at positions 1-3 from the 3' end of the sense strand; in an alternative embodiment, one of the two phosphorothioate internucleoside linkages is located at the 5' end of the sense strand, and the other phosphorothioate linkage is located at the 3' end of the sense strand.
[0102] In an alternative embodiment, the sense strand of the double-stranded oligonucleotide contains one phosphorothioate internucleoside linkage. In an alternative embodiment, one phosphorothioate internucleoside linkage is located between nucleotides at positions 1-2 from the 5' end of the sense strand. In an alternative embodiment, one phosphorothioate internucleoside linkage is located between nucleotides at positions 2-3 from the 5' end of the sense strand.
[0103] Anti-sense strand internucleoside linkage modification:
[0104] In an alternative embodiment, the antisense strand of the double-stranded oligonucleotide contains 2-4 phosphorothioate internucleoside linkages;
[0105] In alternative embodiments, any one of the phosphorothioate internucleoside linkages of the antisense strand of the double-stranded oligonucleotide is located between the nucleotides at positions 1-3 from the 5′ end of the antisense strand, and / or, between the nucleotides at positions 1-3 from the 3′ end of the antisense strand;
[0106] In an alternative embodiment, the antisense strand of the double-stranded oligonucleotide contains 2-4 phosphorothioate internucleoside linkages. In an alternative embodiment, any phosphorothioate internucleoside linkage of the antisense strand of the double-stranded oligonucleotide is located between nucleotides 1-3 from the 5' end of the antisense strand and / or between nucleotides 1-3 from the 3' end of the antisense strand.
[0107] In an alternative embodiment, the antisense strand of the double-stranded oligonucleotide contains four phosphorothioate internucleoside linkages. In an alternative embodiment, the four phosphorothioate internucleoside linkages are located between nucleotides 1-3 from the 5' end and between nucleotides 1-3 from the 3' end of the antisense strand, respectively.
[0108] In an alternative embodiment, the antisense strand of the double-stranded oligonucleotide contains three phosphorothioate internucleoside linkages. In an alternative embodiment, the three phosphorothioate internucleoside linkages are respectively located between the nucleotides at positions 1-2 from the 5' end of the antisense strand and between the nucleotides at positions 1-3 from the 3' end. In an alternative embodiment, the three phosphorothioate internucleoside linkages are respectively located between the nucleotides at positions 1-3 from the 5' end of the antisense strand and between the nucleotides at positions 1-2 from the 3' end.
[0109] In an alternative embodiment, the antisense strand of the double-stranded oligonucleotide contains two phosphorothioate internucleoside linkages. In an alternative embodiment, the two phosphorothioate internucleoside linkages are located between the nucleotides 1-2 from the 5' end and between the nucleotides 1-2 from the 3' end of the antisense strand.
[0110] In an optional embodiment, the double-stranded oligonucleotide is composed of modified nucleotides, and the sense strand is selected from any one of the following (A1)-(A7), and the antisense strand is selected from any one of (A8)-(A14):
[0111] Sense strand, in the direction of 5′ end to 3′ end:
[0112] (A1)AmsAmsGmAmGmGmAfCfUfUmGmCmUmGmCmUmCmAmAm;
[0113] (A2)GmsCmsUmGmCmUmCfAfAfAmUmCmUmAmAmGmGmGmAm;
[0114] (A3)CmsCmsCmUmCmUmGfAfAfAmGmCmUmGmUmUmCmCmUm;
[0115] (A4)GmsAmsAmAmGmCmUfGfUfUmCmCmUmAmUmUmGmCmUm;
[0116] (A5)GmsAmsGmAmGmUmCfUfGfAmGmUmCmAmGmAmGmGmAm;
[0117] (A6)GmsUmsCmUmGmAmGfUfCfAmGmAmGmGmAmCmGmAmUm;
[0118] (A7)CmsUmsGmAmGmUmCfAfGfAmGmGmAmCmGmAmUmGmAm;
[0119] Antisense strand, in the direction of 5′ end - 3′ end:
[0120] (A8)UmsUfsGmAmGmCfAmGmCmAmAmGmUmCfCmUfCmUmUmsUmsGm;
[0121] (A9) UmsCfsCmCmUmUfAmGmAmUmUmUmGmAfGmCfAmGmCmsAmsAm;
[0122] (A10)AmsGfsGmAmAmCfAmGmCmUmUmUmCmAfGmAfGmGmGmsUmsGm;
[0123] (A11)AmsGfsCmAmAmUfAmGmGmAmAmCmAmGfCmUfUmUmCmsAmsGm;
[0124] (A12)UmsCfsCmUmCmUfGmAmCmUmCmAmGmAfCmUfCmUmCmsCmsUm;
[0125] (A13)AmsUfsCmGmUmCfCmUmCmUmGmAmCmUfCmAfGmAmCmsUmsCm;
[0126] (A14)UmsCfsAmUmCmGfUmCmCmUmCmUmGmAfCmUfCmAmGmsAmsCm.
[0127] Optionally, the double-stranded oligonucleotide consists of modified nucleotides and contains at least one 2′-methoxyethyl modified nucleotide, and the sense strand is selected from any one of the following (B1)-(B6), and the antisense strand is selected from any one of (B7)-(B12):
[0128] Sense strand, in the direction of 5′ end to 3′ end:
[0129] (B1)CmsUmsGmUmCmUmAfGfUfUfUmGmUmGmUmUmCmA(moe)Am;
[0130] (B2)UmsCmsUmGmAmAmAfGfCfUfGmT(moe)UmCmCmUmAmUmUm;
[0131] (B3)UmsGmsUmAmC(moe)UmCfAfUfUfCmAmAmGmAmUmCmAmAm;
[0132] (B4)GmsAmsCmUmCmUmGfUfGfAfCmG(moe)UmUmAmAmUmUmUm;
[0133] (B5)GmsUmsGmCmT(moe)GmUfCfUfAfGmUmUmUmGmUmGmUmUm;
[0134] (B6)AmsGmsGmUmGmAmUfGfUfAfCmT(moe)CmAmUmUmCmAmAm;
[0135] Antisense strand, in the 5′-to-3′ direction:
[0136] (B7)UmsUfsGmAmAmCfAmCmAmAfAmCmUmAfG(moe)AfCmAmGmsCmsAm;
[0137] (B8)AmsAfsUmAmGmGfAmAmCfAmGmCmUmUfT(moe)CfAmGmAmsGmsGm;
[0138] (B9)UmsUfsGmAmUmCfUmUmGmAfAmUmGmAfG(moe)UfAmCmAmsUmsCm;
[0139] (B10)AmsAfsAmUmUmAfAmCmGfUmCmAmCmAfG(moe)AfGmUmCmsUmsUm;
[0140] (B11)AmsAfsCmAmCmAfAmAmCmUfAmGmAmCfA(moe)GfCmAmCmsAmsGm;
[0141] (B12)UmsUfsGmAmAmUfGmAmGmUfAmCmAmUfC(moe)AfCmCmUmsCmsGm。
[0142] Optionally, the double-stranded oligonucleotide is selected from any one of the following sense strand and antisense strand combinations:
[0143] RX004007, whose sense strand is (A1), and antisense strand is (A8);
[0144] RX004010, whose sense strand is (A2) and antisense strand is (A9);
[0145] RX004019, whose sense strand is (A3) and antisense strand is (A10);
[0146] RX004021, whose sense strand is (A4), and antisense strand is (A11);
[0147] RX004025, whose sense strand is (A5), and antisense strand is (A12);
[0148] RX004026, whose sense strand is (A6) and antisense strand is (A13);
[0149] RX004027, whose sense strand is (A7), and antisense strand is (A14);
[0150] In an alternative embodiment, the double-stranded oligonucleotide is selected from RX004025, RX004026 or RX004027.
[0151] Optionally, the double-stranded oligonucleotide is selected from any one of the following sense strand and antisense strand combinations:
[0152] RX004170, whose sense strand is (B1), and antisense strand is (B7);
[0153] RX004171, whose sense strand is (B2), and antisense strand is (B8);
[0154] RX004172, whose sense strand is (B3), and antisense strand is (B9);
[0155] RX004173, whose sense strand is (B4), and antisense strand is (B10);
[0156] RX004174, whose sense strand is (B5), and antisense strand is (B11);
[0157] RX004175, the sense strand is (B6), and the antisense strand is (B12).
[0158] According to one aspect of the present invention, a double-stranded oligonucleotide conjugate is provided, wherein the double-stranded oligonucleotide conjugate comprises the double-stranded oligonucleotide of the aforementioned embodiment and a conjugation group; wherein the conjugation group comprises a pharmaceutically acceptable targeting group and / or a delivery auxiliary group;
[0159] In an optional embodiment, the targeting group specifically targets liver tissue;
[0160] In an alternative embodiment, the targeting group is selected from a ligand having affinity for the asialoglycoprotein receptor;
[0161] In an optional embodiment, the 3′ end, the 5′ end and / or the middle position of the double-stranded oligonucleotide is modified by 1, 2, 3, 4, 5 or 6 conjugated groups;
[0162] In an alternative embodiment, the conjugated group is linked to the 3′ terminal nucleotide of the sense strand;
[0163] In an alternative embodiment, the conjugated group comprises N-acetylgalactosamine or a derivative thereof unit.
[0164] In an optional embodiment, the double-stranded oligonucleotide is covalently conjugated to a conjugation group containing an N-acetylgalactosamine unit, and the double-stranded oligonucleotide is as shown in formula (I) or formula (II);
[0165]
[0166] Wherein, in formula (II) and formula (IIIa), Nu represents the double-stranded oligonucleotide;
[0167] In formula (IIIa), m is 1, 2, 3 or 4; Z, p, q, R3, L and Y are defined as follows: Z is each independently selected from hydroxyl or thiol; p is each independently selected from 1, 2 or 3; q is each independently selected from 1, 2 or 3; each R3 is each independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkoxy; L is a C1-C30 alkylene chain, or one or more C atoms in the chain are substituted by any substituent selected from O, S, NH or -NH-C(O)-; Y is each independently NH, O or S;
[0168] Optionally, the above conjugated group is linked to the 3' end of the sense strand of the double-stranded oligonucleotide.
[0169] In an alternative embodiment, the double-stranded oligonucleotide conjugate is as shown in formula (III);
[0170]
[0171] Among them, the double helix structure in formula (III) represents the double-stranded oligonucleotide, wherein the 3′ end of the sense strand of the double-stranded oligonucleotide is connected to the conjugated group;
[0172] Wherein X is O or S.
[0173] According to one aspect of the present invention, there is provided a use of the above double-stranded oligonucleotide or the above double-stranded oligonucleotide conjugate in the preparation of a drug for alleviating, preventing and / or treating a disease or condition mediated by the USP20 gene;
[0174] In alternative embodiments, the disease or condition comprises a cardiovascular disease or a dyslipidemia disease;
[0175] In an alternative embodiment, the cardiovascular disease comprises atherosclerotic cardiovascular disease;
[0176] In an optional embodiment, the dyslipidemia includes elevated serum cholesterol and / or triglyceride levels, elevated low-density lipoprotein cholesterol or elevated apolipoprotein B (ApoB).
[0177] In an optional embodiment, the dyslipidemia includes, but is not limited to, hyperlipidemia in mammals, various types of hypercholesterolemia, such as, but not limited to, non-familial hypercholesterolemia, polygenic hypercholesterolemia or familial hypercholesterolemia.
[0178] In an optional embodiment, the disease or condition includes, but is not limited to, one or more of atherosclerosis, hypercholesterolemia, hypertriglyceridemia, acute coronary syndrome, dyslipidemia, myocardial infarction, coronary artery disease, stroke, coronary artery disease, cardiovascular disease, diabetes, hyperlipidemia and kidney disease.
[0179] According to one aspect of the present invention, there is also provided a pharmaceutical composition, which comprises the above-mentioned double-stranded oligonucleotide, its isomers or pharmaceutically acceptable salts thereof, or the above-mentioned double-stranded oligonucleotide conjugate, its isomers or pharmaceutically acceptable salts thereof; and also comprises a therapeutic agent and / or pharmaceutically optional excipients.
[0180] In an optional embodiment, the therapeutic agent includes, but is not limited to, a small molecule drug, an antibody, an antibody fragment or an oligonucleotide.
[0181] In an optional embodiment, pharmaceutically optional excipients include, but are not limited to, at least one of solvents, buffers (such as saline, phosphate buffer or glucose solution), excipients, diluents, disintegrants, binders, lubricants, sweeteners, flavoring agents and preservatives.
[0182] In an optional embodiment, pharmaceutically optional excipients include excipients, which include but are not limited to vehicles, carriers, diluents and / or delivery polymers, specifically including but not limited to liposomes, nanolipid particles, protamine or high molecular polymers (such as polyethyleneimine). Adding the excipient to a pharmaceutical composition comprising the aforementioned oligonucleotides can form a pharmaceutical preparation suitable for in vivo delivery to a subject (including humans).
[0183] In an optional embodiment, the pharmaceutical composition comprises an effective amount of the aforementioned double-stranded oligonucleotide and at least one pharmaceutically acceptable excipient, wherein "effective amount" refers to the amount of the double-stranded oligonucleotide that can effectively produce the expected pharmacological therapeutic effect.
[0184] In an alternative embodiment, the excipient includes a pharmaceutically acceptable carrier.
[0185] According to one aspect of the present invention, a kit is also provided, characterized in that the kit comprises the above-mentioned double-stranded oligonucleotide or the above-mentioned double-stranded oligonucleotide conjugate, or the above-mentioned pharmaceutical composition.
[0186] In an alternative embodiment, the double-stranded oligonucleotide may be provided in one container in the kit.
[0187] In an alternative embodiment, the kit further comprises at least one container providing a pharmaceutically acceptable excipient.
[0188] In an optional embodiment, the kit may further include other ingredients, such as the aforementioned therapeutic agent and / or the aforementioned pharmaceutically acceptable excipient, such as a stabilizer or a preservative. The other ingredients may be packaged in the same container as the aforementioned double-stranded oligonucleotide, or optionally partly or completely packaged in the same container as the aforementioned double-stranded oligonucleotide. In an optional embodiment, the aforementioned excipient is packaged in the same container as the double-stranded oligonucleotide; in an optional embodiment, the aforementioned excipient, such as saline or glucose solution, is packaged in different containers. In an optional embodiment, the aforementioned therapeutic agent and the double-stranded oligonucleotide are packaged in different containers;
[0189] In an optional embodiment, any component in the kit, including but not limited to the aforementioned double-stranded oligonucleotide, pharmaceutical composition, pharmaceutically acceptable excipients and / or other therapeutic agents can be provided in any form, such as liquid form, dry form or lyophilized form.
[0190] In an optional embodiment, any component in the kit, including but not limited to the aforementioned double-stranded oligonucleotide, pharmaceutical composition, pharmaceutically acceptable excipients and / or other therapeutic agents is substantially pure, more preferably sterile.
[0191] In an alternative embodiment, the kit provides sterile solvents and / or buffers, such as sterile water.
[0192] According to one aspect of the present invention, a method for inhibiting USP20 gene expression is also provided, the method comprising administering the above double-stranded oligonucleotide or the above double-stranded oligonucleotide conjugate, or the above pharmaceutical composition to a subject.
[0193] In an alternative embodiment, the method comprises contacting cells of a subject with the double-stranded oligonucleotide or its conjugate or a pharmaceutical composition comprising the same.
[0194] In an optional embodiment, the subject is a mammal, such as a primate, a rodent or a human. Specific examples include, but are not limited to, cattle, horses, dairy cows, pigs, sheep, goats, rats, mice, guinea pigs, hamsters, dogs, cats, rabbits, camels, donkeys, deer, minks, chickens, ducks, geese, turkeys, fighting cocks or humans. Or any tissue or any cell from the aforementioned subjects.
[0195] In an optional embodiment, the subject is a cell; the method comprises contacting the cell with the double-stranded oligonucleotide or the pharmaceutical composition with the cell in sufficient amount to obtain degradation of the mRNA transcript of the target gene, thereby inhibiting the expression of the target gene in the cell. In an optional embodiment, the expression of the target gene is inhibited by at least 30%, at least about 40%, at least about 50%, at least about 60%, or at least 70%.
[0196] In an alternative embodiment, the method of inhibiting gene expression is for non-diagnostic and non-therapeutic purposes, such as inhibiting USP20 gene expression in cells in vitro as described above.
[0197] In alternative embodiments, the method is for non-diagnostic and non-therapeutic purposes.
[0198] According to one aspect of the present invention, there is also provided a method for alleviating, treating and / or preventing a disease or condition mediated by USP20, the method comprising administering the above double-stranded oligonucleotide or the above double-stranded oligonucleotide conjugate to a subject, or administering the above pharmaceutical composition to a subject;
[0199] In an optional embodiment, the USP20-mediated disease or condition includes a disease associated with the mRNA level of USP20 gene expression;
[0200] In an optional embodiment, the disease or condition includes atherosclerosis, hypercholesterolemia, hypertriglyceridemia, acute coronary syndrome, dyslipidemia, myocardial infarction, coronary artery disease, stroke, coronary artery disease, cardiovascular disease, diabetes, hyperlipidemia, type 2 diabetes, and kidney disease;
[0201] In alternative embodiments, the disease or condition comprises hypercholesterolemia, dyslipidemia or hyperlipidemia.
[0202] In an optional embodiment, the aforementioned double-stranded oligonucleotide and / or the aforementioned pharmaceutical composition is used to reduce the concentration of low-density lipoprotein (LDL) and / or low-density lipoprotein cholesterol (LDL-C) in serum or to prepare a product for reducing the concentration of low-density lipoprotein (LDL) and / or low-density lipoprotein cholesterol (LDL-C) in serum.
[0203] In an alternative embodiment, the aforementioned pharmaceutical composition can be administered by any suitable means, such as in the form of an injection or infusion solution (e.g., subcutaneously, intramuscularly or intravenously), and the administration of the aforementioned double-stranded oligonucleotide or the aforementioned pharmaceutical composition includes but is not limited to single administration or multiple administration. The dosage range is 0.1 mg / kg to 100 mg / kg, 0.5 mg / kg to 50 mg / kg, such as 3 mg / kg, 10 mg / kg or 33 mg / kg.
[0204] It is well known to those skilled in the art that the modified nucleotide groups can be introduced into the siRNA of the present invention by using nucleoside monomers with corresponding modifications: methods for preparing nucleoside monomers with corresponding modifications and methods for introducing modified nucleotide groups into siRNA are also well known to those skilled in the art. All modified nucleoside monomers can be purchased commercially or prepared using known methods.
[0205] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.
[0206] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0207] Unless otherwise specified, the siRNA sequences used in the following examples were commissioned to Kunshan Aotai Biotechnology Co., Ltd. for synthesis; PCR primer synthesis was commissioned to Sangon Biotechnology (Shanghai) Co., Ltd.; cervical cancer Hela cells were purchased from Wuhan Pronocell Life Science Co., Ltd.; experimental animals BALB / c mice and C57BL / 6J mice were purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.; B6-Ob mice were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd., Changzhou Branch; mouse serum samples were tested using a fully automatic biochemical detector at Suzhou Xishan Biotechnology Co., Ltd.
[0208] Unless otherwise stated in the following examples, the real-time PCR detection data of the in vivo activity experiments involved all used the ΔΔCt method to perform relative quantitative calculation of the target gene mRNA in each test group. The calculation method is summarized as follows:
[0209] ΔCt(test group) = Ct(test group target gene) – Ct(test group reference gene)
[0210] ΔCt(control group) = Ct(control group target gene) – Ct(control group internal reference gene)
[0211] ΔΔCt(test group) = ΔCt(test group) - ΔCt(control group average)
[0212] ΔΔCt(control group) = ΔCt(control group) - ΔCt(control group average)
[0213] The mRNA expression level of the target gene in the test group was normalized with the control group as the benchmark, and the remaining expression level of the target gene mRNA in the control group was defined as 100%;
[0214] Relative residual expression level of target gene mRNA in the test group = 2 -ΔΔCt (test group) × 100%;
[0215] The target gene mRNA inhibition rate of the test group = 100% - the relative expression level of the target gene mRNA of the test group.
[0216] Unless otherwise stated in the following examples, the in vivo activity test data are based on The experimental data were plotted and analyzed using GraphPad prism 8.0 software.
[0217] Unless otherwise stated in the following examples, the reagent ratios provided are calculated by volume ratio (v / v).
[0218] The base composition and modification meanings in the following embodiments are as follows: capital letters A (adenine), U (uracil), G (guanine), C (cytosine) and T (thymine, also represented by uracil in the sequence table) represent the base composition of the nucleotides, respectively; lowercase letter m indicates that the nucleotide adjacent to the left of the letter is a 2′-methoxy-modified nucleotide; lowercase letter f indicates that the nucleotide adjacent to the left of the letter is a 2′-fluoro-modified nucleotide; (moe) indicates that the nucleotide adjacent to the left of the combination mark is a 2′-methoxyethyl-modified nucleotide; lowercase letter s indicates that the two nucleotides adjacent to the left and right of the letter are connected by a thiophosphate bond; L96 represents a conjugated group connected to Nu as shown in the following formula (I).
[0219]
[0220] Unless otherwise stated, the reagents and consumables (Table 3) and instruments and equipment (Table 4) used in the following examples are all commercially available products from the following manufacturers:
[0221] Table 3 Main reagents and consumables
[0222] name factory 1× PBS Zhongke Maichen (Beijing) Technology Co., Ltd. DMEM medium Zhongke Maichen (Beijing) Technology Co., Ltd. <![CDATA[Opti-MEM TM Culture medium]]> Gibco serum Sigema Pancreatin Zhongke Maichen (Beijing) Technology Co., Ltd. Dual Antibody BBI Lipofectamine RNAiMax Invitrogen Nucleic acid extraction or purification kit Zhejiang Hanwei Technology Co., Ltd. RevertAid First Strand cDNA Synthesis Kit Thermo Fisher Scientific TaqMan Fast Advanced Master Mix Thermo Fisher Scientific SYBR Select Master Mix Thermo Fisher Scientific Hanwei RNA Extraction Kit Zhejiang Hanwei Technology Co., Ltd. RNALater Thermo Fisher Scientific
[0223] Table 4 Main instruments and equipment
[0224]
[0225]
[0226] In the following examples, USP20 mRNA refers to mRNA having a sequence shown in Genbank registration number NM_001110303.4. Further, unless otherwise specified, in the following examples, "target gene" refers to a gene that transcribes the above USP20 mRNA, and "target mRNA" refers to the above USP20 mRNA.
[0227] Example 1: Synthesis of siRNA
[0228] The siRNA sequence (single-stranded siRNA) to be synthesized was introduced into the ABI394 synthesizer, and Universal CPG / PS was used as the carrier to synthesize according to the set synthesis program. The introduction of each base required four steps of DMTr removal, coupling, oxidation and capping. 2′-OMe, 2′-F and 2′-MOE modified nucleoside phosphoramidite monomers were purchased from Shanghai Zhaowei Technology Development Co., Ltd. 5-Ethylthio-1H-tetrazole (ETT) was used as an activator (0.6M acetonitrile solution), 0.2M hydrogenated xanthanone dissolved in a 1:1 volume ratio of acetonitrile and pyridine (Suzhou Kelema) solution was used as a thiolation reagent, and 0.05M iodine dissolved in a 9:1 volume ratio of pyridine and water solution (Suzhou Kelema) was used as an oxidant.
[0229] After the synthesis, the carrier was removed and blown dry, and concentrated ammonia was used for deprotection (50°C, 16h). After the reaction was completed, it was placed in a -20°C refrigerator for cooling for 10min. After centrifugation, the supernatant was transferred to another centrifuge tube, concentrated to dryness, and purified by RP-HPLC. The mobile phase A was 0.1M TEAA and the mobile phase B was acetonitrile. The purified and collected fractions were subjected to HPLC, MS and UV detection. The qualified fractions were collected and freeze-dried to obtain single-stranded siRNA. The obtained single-stranded siRNA was annealed to finally obtain double-stranded siRNA.
[0230] The nucleotide sequence information of the siRNA involved in the following examples and the modification information of the siRNA are shown in Table 2 above.
[0231] Example 2 Evaluation of in vitro activity of ubiquitin specific peptidase 20 (USP20) siRNA
[0232] In this example, an in vitro cell screening method was used to evaluate the in vitro inhibitory activity of RX004001 to RX004169 targeting USP20 (NM_001110303.4) and the negative control compound RX000001 on the target gene USP20 in the human cervical cancer cell line Hela.
[0233] (1) Experimental methods:
[0234] (1.1) Preparation of test samples: After centrifugation of each siRNA test sample, add an appropriate amount of DEPC H2O to dissolve it according to the specifications of each tube to prepare a 20 μM stock solution, and then further dilute the stock solution with DEPC H2O to 0.4 μM and 0.04 μM working solutions. Finally, the screening test was carried out with a final duplex concentration of 10 nM and 1 nM.
[0235] (1.2) Cell culture, 96-well transfection and detection:
[0236] Hela cells grown to near confluence were digested with trypsin, washed, and cell suspensions were prepared for plating in 96-well plates.
[0237] 5 μL of 0.4 μM and 0.04 μM working solutions were dispersed in 20 μL Opti-MEM to form siRNA mixtures, and 0.2 μL RNAiMAX was dispersed in 24.8 μL Opti-MEM. After incubation for 5 minutes, each siRNA mixture was mixed and incubated for 10 minutes to form transfection complexes. 150 μL of cell suspension (12,000 cells) was added to the transfection complexes in each well, and the 96-well plate was placed in an incubator and continued to be cultured for 24 hours.
[0238] The 96-well plate was removed, the cells were lysed, and the lysate was diluted. A one-step qPCR kit (Thermo Fisher, Power SYBR Green RNA-to-CT TM1-Step, 4389986) The expression of target gene mRNA in Hela cells was detected on a fluorescent quantitative PCR instrument (Roche, LightCycler 480). In this real-time fluorescent quantitative PCR method, the TATA-box binding protein (TBP) gene was used as an internal reference gene, and primers for the target gene and the TBP internal reference gene were used to detect the target gene and the TBP internal reference gene, respectively. The sequences of the detection primers are shown in Table 5.
[0239] Table 5 Sequences of detection primers
[0240]
[0241] In the real-time fluorescence quantitative PCR method, the ΔΔCt method is used according to the technical method described in the embodiment to perform relative quantitative calculation of the expression level and inhibition rate of the target gene mRNA in each test group.
[0242] (2) Experimental results: The in vitro residual activity data of RX004001 to RX004169 targeting USP20 and the negative control compound RX000001 after transfection of Hela cell lines are shown in Table 6.
[0243] Table 6 Residual activity of target genes in Hela cells after administration of each siRNA
[0244]
[0245]
[0246]
[0247] Example 3 Evaluation of in vivo activity of siRNA targeting USP20 in the mouse high pressure hydrodynamic injection model (HDI)
[0248] In this example, the Balb / c mouse hydrodynamic injection model was used to evaluate the inhibitory activity of the same USP20 target siRNA sense strand 3′ end conjugated to the L96 vector conjugates RZ004001 to RZ004027 on the target gene USP20.
[0249] (1) Experimental methods:
[0250] (1.1) Plasmid construction: pcDNA-CMV-RG004 plasmid was constructed by Sangon Biotech (Shanghai) Co., Ltd. The full length of USP20 (NM_001110303.4) was inserted into the multiple cloning site of pcDNA-CMV vector by whole gene synthesis.
[0251] (1.2) Mouse model construction: The Balb / c mouse high-pressure hydrodynamic injection model is a model established by rapidly injecting the pcDNA-CMV-RG004 plasmid solution into the mouse through the tail vein of the mouse. On the fourth day of the experiment, the mouse was injected with 10 μg of pcDNA-CMV-RG004 through the tail vein hydrodynamics within 5 seconds, and the injection volume was 8% of the mouse body weight. The plasmid DNA for injection was diluted with physiological saline, and the solution was prepared before injection and stored at 4°C.
[0252] (1.3) Animal grouping, drug administration and tissue sample collection: 6-8 week old Balb / c mice were randomly grouped according to body weight (all female), with 5 mice in each group. Each test group was given a predetermined dose of drug conjugate and a PBS control group was added. The drug dose for all mice was calculated according to body weight, and a single dose was given by subcutaneous injection in the abdomen. Each drug conjugate was administered in the form of 0.1 mg / mL (calculated as siRNA) PBS solution, and the administration volume was 10 mL / kg mouse body weight, that is, the dosage of each drug conjugate was 1 mg / kg mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PBS solution (without drug conjugate). The day of administration was recorded as day 1 (recorded as D1), plasmid injection was performed on the 4th day after administration (recorded as D4), and 5 mice in all groups were killed on the 5th day (recorded as D5). The mice were grossly dissected and the liver tissue of each mouse was collected. The liver tissue was cut into small pieces of about 2 mm3 and preserved with RNA later.
[0253] For each mouse, an appropriate amount of liver tissue sample was taken out from RNAlater, and the liver tissue sample was broken in a Tissuelyser II fully automatic tissue homogenizer for 60 seconds, and then the total RNA was extracted using a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd., GO-MNTR-100) according to the standard operating procedures for total RNA extraction.
[0254] For each mouse, 1 μg of total RNA was taken respectively, and a reverse transcription kit (Thermo Fisher Scientific, RevertAid First Strand cDNA Synthesis Kit, K1622) was used and Oligo (dT) 18 reverse transcription primer was selected. According to the method recorded in the reverse transcription kit manual, 20 μL reverse transcription system was configured and the reverse transcription reaction was completed. After the reaction was completed, 60 μL RNase-Free water was added to the reverse transcription system to obtain a cDNA solution. Then, the expression of the target gene mRNA in the animal was detected using a real-time fluorescence quantitative PCR kit (Thermo Fisher Scientific, TaqMan Fast Advanced Master Mix, 4444557) fluorescence quantitative PCR instrument (Bio-Rad, CFX Opus 384). In the real-time fluorescence quantitative PCR method, the Nero gene on the plasmid backbone was used as an internal reference gene, and the primer for the target gene and the primer for the Nero internal reference gene were used to detect the target gene and the Nero internal reference gene respectively. The sequence of the detection primer is shown in Table 7.
[0255] Table 7 Sequences of detection primers
[0256]
[0257] According to the method described in the instruction manual of the real-time fluorescence quantitative PCR kit, 10 μL of Real-time PCR reaction system was prepared for each PCR detection well. Each reaction system contained 4 μL of the cDNA solution obtained by the above reverse transcription reaction, 5 μL of TaqMan TM Fast Advanced Master Mix (2×), 0.15 μL 10 μM upstream primer, 0.15 μL 10 μM downstream primer (primer information see Table 7), 0.15 μL 10 μM probe primer, 0.55 μL RNase-Free H2O. The configured reaction system is placed on a real-time fluorescence quantitative PCR instrument (Bio-Rad, CFX Opus 384), and a two-step method is used for Real-time PCR amplification. The amplification program is 50°C 2min, then 95°C pre-denaturation 20s, 95°C denaturation 3s, 60°C annealing and extension 30s, and the process of denaturation, annealing and extension is repeated for 40 cycles. In the real-time fluorescence quantitative PCR method, the expression level and inhibition rate of the target gene mRNA in each test group are relatively quantitatively calculated using the ΔΔCt method according to the technical method described in the embodiment.
[0258] (2) Experimental results: The experimental results are as follows Figure 1As shown in Table 8, the results showed that at a dose of 1 mg / kg siRNA, RZ004007, RZ004010, RZ004019, RZ004021, RZ004025, RZ004026, and RZ004027 could significantly inhibit USP20 mRNA expression.
[0259] Table 8 Inhibitory activity of target genes in mice after administration of siRNA conjugates of RZ004001 to RZ004027
[0260] Group % Remaining Activity STDEV Group % Remaining Activity STDEV PBS 100 20.06 RZ004014 81.44 15.68 RZ004001 81.6 11.08 RZ004015 62.2 8.9 RZ004002 96.24 18.49 RZ004016 82.79 31.8 RZ004003 73.08 11.94 RZ004017 116.12 10.17 RZ004004 67.16 26.96 RZ004018 102.74 20.65 RZ004005 106.66 21.51 RZ004019 47.54 18.22 RZ004006 91.38 45.39 RZ004020 72.86 7.36 RZ004007 29.34 12.06 RZ004021 32.58 7.53 RZ004008 103.8 20.94 RZ004022 91.65 10 RZ004009 96.39 10.89 RZ004023 86.15 25.83 RZ004010 42.56 11.33 RZ004024 87.77 29.78 RZ004011 74.33 16.11 RZ004025 40.28 10.96 RZ004012 83.17 22.64 RZ004026 46.61 4.81 RZ004013 97.82 23.16 RZ004027 6.46 0.93
[0261] Example 4 In vitro activity evaluation of differently modified siRNA targeting USP20
[0262] This example uses the target gene inhibitory activity assessment method in Hela to evaluate the inhibitory activity of various differently modified USP20-targeting siRNAs (RZ004027 to RZ004054) on the target gene USP20 in cells.
[0263] (1) Experimental methods:
[0264] (1.1) Preparation of test samples: After centrifugation of each siRNA test sample, add an appropriate amount of PBS according to the specifications of each tube to dissolve it and prepare a 20 μM stock solution. The stock solution is further diluted with PBS to 1 μM and 0.1 μM working solutions. The dosage test is carried out with a final duplex concentration of 10 nM and 1 nM.
[0265] (1.2) 96-well transfection and detection: Hela cells grown to near confluence were digested with trypsin, and the cells were washed to prepare a cell suspension. 100 μL of cell suspension was added to each well of the 96-well plate, and the number of cells in each well was 12,000 cells. The plates were cultured in a 37°C, 5% CO2 incubator. When the cells were attached for 24 hours, the DMEM medium in the 96-well plate was discarded, and 80 μL of Opti-MEM medium was added to each well. The 96-well plate was then placed in an incubator for further culture. 1 μL of 1 μM and 0.1 μM working solutions were dispersed in 9 μL Opti-MEM to form an siRNA mixture, and 0.3 μL RNAiMAX was dispersed in 9.7 μL Opti-MEM and mixed with each siRNA mixture to form a transfection complex. The transfection complex was incubated at room temperature for 10 minutes, and then the transfection complex was added to the 96-well plate at 20 μL / well. After culturing for 4 h, each well was supplemented with 100 μL of DMEM medium containing 20% FBS, and the 96-well plate was placed in an incubator and continued to be cultured for 24 h.
[0266] The 96-well plate was taken out, and total RNA was extracted using a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd., GO-MNTR-100) according to the standard operating procedures for total RNA extraction.
[0267] Use reverse transcription kit (Thermo Fisher Scientific company, RevertAid First StrandcDNASynthesis Kit, K1622) and select Oligo (dT) 18 reverse transcription primer, configure 20 μ L reverse transcription system and complete reverse transcription reaction according to the method recorded in the reverse transcription kit specification.Then use real-time fluorescence quantitative PCR kit (Thermo Fisher Scientific company, TaqMan Fast Advanced Master Mix, 4444557) to detect the expression of target gene mRNA in Hela cells on fluorescence quantitative PCR instrument (Roche company, LightCycler 480).In this real-time fluorescence quantitative PCR method, using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as internal reference gene, use primers for target gene and primers for GAPDH internal reference gene to detect target gene and GAPDH internal reference gene respectively.The sequence of detection primers is shown in Table 9.
[0268] Table 9 Sequences of detection primers
[0269]
[0270] According to the method described in the instruction manual of the real-time fluorescence quantitative PCR kit, 10 μL of Real-time PCR reaction system was prepared for each PCR detection well. Each reaction system contained 4 μL of the cDNA solution obtained by the above reverse transcription reaction, 5 μL of TaqMan TMFast Advanced Master Mix (2×), 0.15 μL 10 μM upstream primer, 0.15 μL 10 μM downstream primer (primer information see Table 9), 0.15 μL 10 μM probe primer, 0.55 μL RNase-Free H2O. The configured reaction system is placed on a real-time fluorescence quantitative PCR instrument (Bio-Rad, CFX Opus 384), and a two-step method is used for Real-time PCR amplification. The amplification program is 50°C 2min, then 95°C pre-denaturation 20s, 95°C denaturation 3s, 60°C annealing and extension 30s, and the process of denaturation, annealing and extension is repeated for 40 cycles. In the real-time fluorescence quantitative PCR method, the expression level and inhibition rate of the target gene mRNA in each test group are relatively quantitatively calculated using the ΔΔCt method according to the technical method described in the embodiment.
[0271] (2) Experimental results: The results of Example 4 show that at 10 nM and 1 nM doses, the siRNA conjugates with different modifications can significantly inhibit the expression of USP20 mRNA in Hela cells ( Figure 2 , Table 10).
[0272] Table 10 Inhibitory activity of target genes in Hela cells after administration of siRNA conjugates of RZ004027-RZ004054
[0273]
[0274]
[0275] Example 5 In vivo inhibitory activity of siRNA conjugates targeting USP20 in B6-Ob model mice
[0276] In this example, a method for evaluating the in vivo target gene inhibitory activity in mice was used to evaluate the inhibitory activity of RZM04001 on the target gene USP20 in mice.
[0277] (1) Experimental methods:
[0278] (1.1) Animal grouping, drug administration, and tissue sample collection
[0279] Four 6-8 week old male C57BL / 6J mice were subcutaneously injected with PBS in the abdomen, four male B6-Ob mice were subcutaneously injected with PBS in the abdomen, and four male B6-Ob mice were subcutaneously injected with RZM04001 in the abdomen. The dosage of all mice was calculated according to body weight, and a single administration was adopted. The drug conjugate RZM04001 was administered in the form of 0.9 mg / ml (calculated as siRNA) of PBS solution, and the administration volume was 10 mL / kg of mouse body weight, that is, the dosage of drug conjugate RZM04001 was 9 mg / kg of mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PBS solution (without drug conjugate). The day of administration was recorded as the first day (recorded as D1)), and all mice in the group were killed on the 15th day after administration (recorded as D15). The mice were grossly dissected and the liver tissue of each mouse was collected, and the liver tissue was cut into small pieces of about 2 mm3 and preserved with RNAlater.
[0280] (1.2) Sample testing:
[0281] For each mouse, an appropriate amount of liver tissue sample was taken from RNA later, and the liver tissue sample was broken in a Tissuelyser II fully automatic tissue homogenizer for 60 seconds, and then the total RNA was extracted using a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd., GO-MNTR-100) according to the standard operating procedures for total RNA extraction.
[0282] For each mouse, 1 μg of total RNA was taken respectively, and a reverse transcription kit (Thermo Fisher Scientific, RevertAid First Strand cDNA Synthesis Kit, K1622) was used and Oligo (dT) 18 reverse transcription primer was selected, and 20 μL reverse transcription system was configured and reverse transcription reaction was completed according to the method recorded in the reverse transcription kit manual. After the reaction was completed, 60 μL RNase-Free water was added to the reverse transcription system to obtain a cDNA solution. Then, the expression of the target gene mRNA in the animal was detected on a fluorescence quantitative PCR instrument (Bio-Rad, CFX Opus 384) using a real-time fluorescence quantitative PCR kit (Thermo Fisher Scientific, SYBR Select Master Mix, 4472908). In the real-time fluorescence quantitative PCR method, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal reference gene, and primers for the target gene and the primers for the Nero internal reference gene were used to detect the target gene and the GAPDH internal reference gene respectively. The sequence of the detection primer is shown in Table 11.
[0283] Table 11 Sequences of detection primers
[0284]
[0285] According to the method described in the instruction manual of the real-time fluorescence quantitative PCR kit, 10 μL Real-time PCR reaction system was configured for each PCR detection well. Each reaction system contained 4 μL cDNA solution obtained by the above reverse transcription reaction, 5 μL SYBR Select Master Mix (2×), 0.3 μL 10 μM upstream primer, 0.3 μL 10 μM downstream primer (primer information see Table N), and 0.4 μL RNase-Free H2O. The configured reaction system was placed on a real-time fluorescence quantitative PCR instrument (Bio-Rad, CFXOpus 384), and Real-time PCR amplification was performed using a three-step method. The amplification program was 95°C pre-denaturation for 10 min, then 95°C denaturation for 30 s, 59°C annealing for 30 s, and 72°C extension for 30 s. The denaturation, annealing and extension process was repeated for 40 cycles. In the real-time fluorescence quantitative PCR method, the expression level and inhibition rate of the target gene mRNA in each test group were relatively quantitatively calculated using the ΔΔCt method according to the technical method described in the embodiment.
[0286] (2) Experimental results:
[0287] The results of Example 5 showed that compared with C57BL / 6J mice (C57BL / 6J group), the expression level of USP20 mRNA in B6-Ob model mice (B6-ObModel group) was significantly increased; after treatment with RZM04001 conjugate (B6-Ob Model+RZM04001 group) in B6-Ob model mice, the expression level of USP20 mRNA in the mice of the drug-treated group was significantly reduced (**P<0.01), and the reduction was 68.98% ( Figure 3 , Table 12).
[0288] Table 12 Inhibitory activity of target genes in mice after administration of RZM04001
[0289]
[0290] Example 6 Regulatory effect of siRNA conjugate targeting USP20 on total cholesterol in B6-Ob model mice
[0291] In this example, an automatic biochemical analyzer was used to detect changes in total cholesterol in mouse serum to evaluate the lipid-regulating effect of RZM04001 in mice.
[0292] (1) Experimental methods:
[0293] (1.1) Animal grouping, drug administration and tissue sample collection:
[0294] Ten male C57BL / 6J mice aged 6-8 weeks were subcutaneously injected with PBS in the abdomen, ten male B6-Ob mice were subcutaneously injected with PBS in the abdomen, and ten male B6-Ob mice were subcutaneously injected with RZM04001 in the abdomen. The dosage of all mice was calculated according to the body weight, and a single administration was adopted. The drug conjugate RZM04001 was administered in the form of 0.9 mg / ml (calculated as siRNA) PBS solution, and the administration volume was 10 mL / kg mouse body weight, that is, the dosage of the drug conjugate RZM04001 was 9 mg / kg mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PBS solution (without drug conjugate). The day of administration was recorded as Day 1 (recorded as D1). The sera of mice in all groups were collected on the 8th day (recorded as D8), 15th day (recorded as D15), 22nd day (recorded as D22), and 29th day (recorded as D29) after administration and sent to Suzhou Xishan Biotechnology Co., Ltd. for detection of total cholesterol in serum using a fully automatic biochemical detector.
[0295] (2) Experimental results:
[0296] The results of Example 6 showed that the cholesterol level in B6-Ob model mice (B6-Ob Model group) was significantly higher than that in C57BL / 6J mice (wt / wt group); after a single subcutaneous injection of RZM04001 conjugate treatment in B6-Ob mice (RZM0001 group), RZM04001 could significantly reduce the CHO expression level in mouse serum ( Figure 4 , Table 13).
[0297] Table 13 Cholesterol levels in mouse serum at different time points after administration of RZM04001
[0298]
[0299] It can be seen from the above examples that the siRNA conjugates of the present invention can effectively reduce the USP20 protein level for a long time.
[0300] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A double-stranded oligonucleotide for inhibiting the expression of USP20 gene, characterized in that: The double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are complementary or substantially complementary to form a double-stranded region; the substantially complementary means that the sense strand and the antisense strand have a mismatch of no more than 3 nucleotides in the double-stranded region; wherein the sense strand comprises at least 15 consecutive nucleotides substantially identical to SEQ ID NO: 349, wherein the substantially identical means that the sense strand has no more than 3 nucleotide differences from at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 349; wherein the antisense strand comprises at least 15 nucleotides and is complementary or substantially complementary to the sense strand; Each nucleotide of the double-stranded oligonucleotide is an unmodified or modified nucleotide; Optionally, at least one nucleotide in the double-stranded oligonucleotide is modified.
2. The double-stranded oligonucleotide according to claim 1, characterized in that The antisense strand is complementary or substantially complementary to at least 15, 16, 17, 18, 19, 20, 21, 22 or 23 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 349, wherein the substantially complementary strand has no more than 3 nucleotide mismatches in the complementary region.
3. The double-stranded oligonucleotide according to claim 1, characterized in that The positive sense strand comprises at least 15 consecutive nucleotides that differ from the nucleotide sequence of SEQID NO: 349 by no more than 2 nucleotides; and, substantially all of the nucleotides of the positive sense strand and the nucleotides of the antisense strand are modified nucleotides, and the length of the double-stranded region is 15-25bp; wherein, substantially all of the modified nucleotides means that the number of unmodified nucleotides on the strand does not exceed 5, preferably does not exceed 3, and more preferably does not exceed 1.
4. The double-stranded oligonucleotide according to claim 1, characterized in that The antisense strand comprises a sequence of at least 15 consecutive nucleotides that differs by no more than 3 nucleotides from any of the antisense sequences listed in Table 1, and wherein the sense strand comprises a sequence of at least 15 consecutive nucleotides that differs by no more than 3 nucleotides from any of the sense sequences listed in Table 1; Optionally, the sense strand comprises a sequence that differs by no more than 2 nucleotides from any sequence in SEQ ID NOs: 1-7 and SEQ ID NOs: 15-183; the antisense strand comprises a sequence that differs by no more than 2 nucleotides from any sequence in SEQ ID NOs. 8-14 and SEQ ID NOs. 184-348; Optionally, the nucleotide sequence of the sense strand differs from any nucleotide sequence selected from SEQ ID NOs: 1-7 and SEQ ID NOs: 15-183 by no more than 1 nucleotide, and / or the nucleotide sequence of the antisense strand differs from any nucleotide sequence selected from SEQ ID NOs. 8-14 and SEQ ID NOs. 184-348 by no more than 1 nucleotide; Optionally, the double-stranded oligonucleotide is selected from one or more of the modified or unmodified double-stranded oligonucleotides shown in the following numbers in Table 1 or Table 2: RN004006, RN004011, RN004015, RN004017, RN004018, RN004019, RN004020, RN004023, RN004024, RN004043, RN00405 3. RN004054, RN004063, RN004066, RN004067, RN004074, RN004076, RN004077, RN004092 , RN004093, RN004094, RN004096, RN004103, RN004110, RN004141, RN004164, RN004166; Optionally, the double-stranded oligonucleotide is selected from the modified or unmodified double-stranded oligonucleotides numbered RN004166, RN004020, RN004094, RN004141, RN004043, RN004164, RN004092; Optionally, the double-stranded oligonucleotide is selected from the modified double-stranded oligonucleotides numbered RN004030, RN004033, RN004041, RN004043, RN004051, and RN004053.
5. The double-stranded oligonucleotide according to any one of claims 1 to 4, characterized in that The sense strand and / or antisense strand contains at least one ribose 2′ hydroxyl group replaced by a large group 2′-O(CH2) n OR substituted nucleotides, wherein n is 1 or 2, and R is selected from: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy; wherein the substituent is selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, amino, cycloalkyl with no more than 6 carbon atoms, aryl or heteroaryl with no more than 12 carbon atoms.
6. The double-stranded oligonucleotide according to any one of claims 1 to 4, characterized in that The nucleotides of the double-stranded oligonucleotide further include one or more of the following modifications; 2′-O-methyl modified nucleotides, 2′-fluoro modified nucleotides, 2′-deoxy nucleotides, 2′-methoxyethyl modified nucleotides, 2′-alkyl modified nucleotides, 2′-amino-modified nucleotides, 2′-alkoxy modified nucleotides, locked nucleic acid modifications, non-locked nucleic acid modifications, 2′-O-allyl modifications, 2′-C-allyl modifications, abasic nucleotides, morpholino nucleotides, conformationally restricted nucleotides, constrained ethyl nucleotides, phosphoramidate modifications; Optionally, the modification is selected from at least one of 2′-O-methyl modified nucleotides, 2′-fluoro-modified nucleotides, 2′-deoxynucleotides, and phosphorothioate modified nucleotides; Optionally, the nucleotides of the sense strand and / or the antisense strand of the double-stranded oligonucleotide are all modified nucleotides; Optionally, the sense strand of the double-stranded oligonucleotide is 17-21 nt long, and the antisense strand is 19-23 nt long; wherein, in the direction from the 5′ end to the 3′ end, at least three of the nucleotides at positions 7-10 of the nucleotide sequence in the sense strand are fluorinated modified nucleotides, and the nucleotides at the remaining positions are 2′-O-methyl modified regions or 2′-methoxyethyl modified nucleotides; at least four of the nucleotides at positions 2, 6, 9-10, 14 and 16 of the nucleotide sequence in the antisense strand are 2′-fluorinated modified nucleotides, and the nucleotides at the remaining positions are 2′-O-methyl modified or 2′-methoxyethyl modified nucleotides; Optionally, the sense strand and / or the antisense strand contains at least one 2′-methoxyethyl modified nucleotide; Optionally, in the direction from 5′ end to 3′ end, the 5′ end of the sense strand comprises 1 or 2 phosphorothioate modified nucleotides; and / or, the 5′ end and 3′ end of the antisense strand each independently comprise 1 or 2 phosphorothioate modified nucleotides.
7. The double-stranded oligonucleotide according to any one of claims 1 to 6, characterized in that The double-stranded oligonucleotide is composed of modified nucleotides, and the sense strand is selected from any one of the following (A1)-(A7), and the antisense strand is selected from any one of (A8)-(A14): Sense strand, in the direction of 5′ end to 3′ end: (A1)AmsAmsGmAmGmGmAfCfUfUmGmCmUmGmCmUmCmAmAm; (A2)GmsCmsUmGmCmUmCfAfAfAmUmCmUmAmAmGmGmGmAm; (A3)CmsCmsCmUmCmUmGfAfAfAmGmCmUmGmUmUmCmCmUm; (A4)GmsAmsAmAmGmCmUfGfUfUmCmCmUmAmUmUmGmCmUm; (A5)GmsAmsGmAmGmUmCfUfGfAmGmUmCmAmGmAmGmGmAm; (A6)GmsUmsCmUmGmAmGfUfCfAmGmAmGmGmAmCmGmAmUm; (A7)CmsUmsGmAmGmUmCfAfGfAmGmGmAmCmGmAmUmGmAm; Antisense strand, in the direction of 5′ end - 3′ end: (A8)UmsUfsGmAmGmCfAmGmCmAmAmGmUmCfCmUfCmUmUmsUmsGm; (A9) UmsCfsCmCmUmUfAmGmAmUmUmUmGmAfGmCfAmGmCmsAmsAm; (A10)AmsGfsGmAmAmCfAmGmCmUmUmUmCmAfGmAfGmGmGmsUmsGm; (A11)AmsGfsCmAmAmUfAmGmGmAmAmCmAmGfCmUfUmUmCmsAmsGm; (A12)UmsCfsCmUmCmUfGmAmCmUmCmAmGmAfCmUfCmUmCmsCmsUm; (A13)AmsUfsCmGmUmCfCmUmCmUmGmAmCmUfCmAfGmAmCmsUmsCm; (A14)UmsCfsAmUmCmGfUmCmCmUmCmUmGmAfCmUfCmAmGmsAmsCm; Optionally, the double-stranded oligonucleotide consists of modified nucleotides and contains at least one 2′-methoxyethyl modified nucleotide, and the sense strand is selected from any one of the following (B1)-(B6), and the antisense strand is selected from any one of (B7)-(B12): Sense strand, in the direction of 5′ end to 3′ end: (B1)CmsUmsGmUmCmUmAfGfUfUfUmGmUmGmUmUmCmA(moe)Am; (B2)UmsCmsUmGmAmAmAfGfCfUfGmT(moe)UmCmCmUmAmUmUm; (B3)UmsGmsUmAmC(moe)UmCfAfUfUfCmAmAmGmAmUmCmAmAm; (B4)GmsAmsCmUmCmUmGfUfGfAfCmG(moe)UmUmAmAmUmUmUm; (B5)GmsUmsGmCmT(moe)GmUfCfUfAfGmUmUmUmGmUmGmUmUm; (B6)AmsGmsGmUmGmAmUfGfUfAfCmT(moe)CmAmUmUmCmAmAm; Antisense strand, in the direction of 5′ end - 3′ end: (B7)UmsUfsGmAmAmCfAmCmAmAfAmCmUmAfG(moe)AfCmAmGmsCmsAm; (B8)AmsAfsUmAmGmGfAmAmCfAmGmCmUmUfT(moe)CfAmGmAmsGmsGm; (B9)UmsUfsGmAmUmCfUmUmGmAfAmUmGmAfG(moe)UfAmCmAmsUmsCm; (B10)AmsAfsAmUmUmAfAmCmGfUmCmAmCmAfG(moe)AfGmUmCmsUmsUm; (B11)AmsAfsCmAmCmAfAmAmCmUfAmGmAmCfA(moe)GfCmAmCmsAmsGm; (B12)UmsUfsGmAmAmUfGmAmGmUfAmCmAmUfC(moe)AfCmCmUmsCmsGm; Wherein, C, G, U, and A represent cytidine-3′-phosphate, guanosine-3′-phosphate, uridine-3′-phosphate, and adenosine-3′-phosphate, respectively; m represents that the nucleotide adjacent to the right of the letter m is a 2′-O-methyl modified nucleotide; f represents that the nucleotide adjacent to the left of the letter f is a 2′-fluorine modified nucleotide; (moe) represents that the nucleotide adjacent to the left of the combination logo is a 2′-methoxyethyl modified nucleotide; s represents that the two nucleotides before and after are connected by a thiophosphate backbone; Optionally, the double-stranded oligonucleotide is selected from any one of the following sense strand and antisense strand combinations: RX004007, whose sense strand is (A1), and antisense strand is (A8); RX004010, whose sense strand is (A2) and antisense strand is (A9); RX004019, whose sense strand is (A3) and antisense strand is (A10); RX004021, whose sense strand is (A4), and antisense strand is (A11); RX004025, whose sense strand is (A5), and antisense strand is (A12); RX004026, whose sense strand is (A6) and antisense strand is (A13); RX004027, whose sense strand is (A7), and antisense strand is (A14); Optionally, the double-stranded oligonucleotide is selected from any one of the following sense strand and antisense strand combinations: RX004170, whose sense strand is (B1), and antisense strand is (B7); RX004171, whose sense strand is (B2), and antisense strand is (B8); RX004172, whose sense strand is (B3), and antisense strand is (B9); RX004173, whose sense strand is (B4), and antisense strand is (B10); RX004174, whose sense strand is (B5), and antisense strand is (B11); RX004175, the sense strand is (B6), and the antisense strand is (B12).
8. A double-stranded oligonucleotide conjugate, characterized in that The double-stranded oligonucleotide conjugate comprises a double-stranded oligonucleotide according to any one of claims 1 to 7 and a conjugated group; wherein the conjugated group comprises a pharmaceutically acceptable targeting group and / or a delivery auxiliary group; Optionally, the targeting group specifically targets liver tissue; Optionally, the targeting group is selected from ligands with affinity for asialoglycoprotein receptors; Optionally, the 3′ end, the 5′ end and / or the middle position of the double-stranded oligonucleotide are modified with 1-6 conjugated groups; Optionally, the conjugated group is linked to the 3′ terminal nucleotide of the sense strand; Optionally, the conjugated group comprises N-acetylgalactosamine or a derivative thereof unit.
9. The double-stranded oligonucleotide conjugate according to claim 8, characterized in that The double-stranded oligonucleotide is covalently conjugated to a conjugation group containing an N-acetylgalactosamine unit, and the double-stranded oligonucleotide is as shown in formula (I) or formula (II); Wherein, Nu in formula (I) and formula (II) represents the double-stranded oligonucleotide; In formula (II), m is 1, 2, 3 or 4; Z, p, q, R3, L and Y are defined as follows: Z is independently selected from hydroxyl or thiol; p is independently selected from 1, 2 or 3; q is independently selected from 1, 2 or 3; each R3 is independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkoxy; L is a C1-C30 alkylene chain, or one or more C atoms in the chain are substituted by any substituent selected from O, S, NH or -NH-C(O)-; Y is independently NH, O or S; Optionally, the above conjugated group is linked to the 3' end of the sense strand of the double-stranded oligonucleotide.
10. The double-stranded oligonucleotide conjugate according to claim 8, characterized in that The double-stranded oligonucleotide conjugate is shown in formula (III); Wherein, the double helix structure in formula (III) represents the double-stranded oligonucleotide, wherein the 3′ end of the sense strand of the double-stranded oligonucleotide is connected to the conjugated group; Wherein X is O or S.
11. Use of the double-stranded oligonucleotide according to any one of claims 1 to 7 or the double-stranded oligonucleotide conjugate according to any one of claims 8 to 10 in the preparation of a medicament for alleviating, preventing and / or treating a disease or condition mediated by the USP20 gene; Optionally, the disease or disorder comprises a cardiovascular disease or a dyslipidemic disease.
12. A pharmaceutical composition, characterized in that The invention comprises a double-stranded oligonucleotide according to any one of claims 1 to 7, an isomer thereof or a pharmaceutically acceptable salt thereof, or a double-stranded oligonucleotide conjugate according to any one of claims 8 to 10, an isomer thereof or a pharmaceutically acceptable salt thereof; and further comprises a therapeutic agent and / or a pharmaceutically optional excipient.
13. A kit, characterized in that The kit comprises the double-stranded oligonucleotide according to any one of claims 1 to 7 or the double-stranded oligonucleotide conjugate according to any one of claims 8 to 10, or the pharmaceutical composition according to claim 12.
14. A method for inhibiting USP20 gene expression, characterized in that: The method comprises administering to a subject the double-stranded oligonucleotide of any one of claims 1 to 7 or the double-stranded oligonucleotide conjugate of any one of claims 8 to 10, or the pharmaceutical composition of claim 12; Optionally, the method comprises contacting the subject's cells with the double-stranded oligonucleotide or its conjugate or a pharmaceutical composition comprising the same.
15. A method for alleviating, treating and / or preventing a disease or condition mediated by USP20, characterized in that: The method comprises administering to a subject the double-stranded oligonucleotide of any one of claims 1 to 7 or the double-stranded oligonucleotide conjugate of any one of claims 8 to 10, or administering to a subject the pharmaceutical composition of claim 12; Optionally, the USP20-mediated disease or condition comprises a disease associated with the level of mRNA expressed by the USP20 gene; Optionally, the disease or condition comprises atherosclerosis, hypercholesterolemia, hypertriglyceridemia, acute coronary syndrome, dyslipidemia, myocardial infarction, coronary artery disease, stroke, coronary artery disease, cardiovascular disease, diabetes, hyperlipidemia, type 2 diabetes, and kidney disease; Optionally, the disease or disorder comprises hypercholesterolemia, dyslipidemia or hyperlipidemia.
Citation Information
Cited By
Oligonucleotide, oligonucleotide conjugate, composition, and use thereof
WO2026139046A1
Rnai construct for inhibiting expression of USP20 gene and use thereof
WO2026195058A1
